dostarlimab
gsk
['rectal', 'dostarlimab']
impressive results with neoadjuvant dostarlimab alone for stage ii/iii dmmr rectal cancer, with a 100% clinical cr rate in the first 14 consecutive patients treated. no crt or surgery needed to date and no relapses during the current follow-up period . #asco22
The latest clinical diagnostic, treatment & personalized medicine advances & more from Nature Reviews Clinical Oncology, a reviews journal. Tweets by the eds.